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gp78 is a membrane-anchored ubiquitin ligase
mediating the degradation of HMG-CoA reductase
(HMGCR) and Insig-1. As a rate-limiting enzyme in
cholesterol biosynthesis, HMGCR undergoes rapid
sterol-promoted degradation. In contrast, destruc-
tion of Insig-1 releases its inhibition on SREBP and
stimulates the expression of lipogenic genes. Thus,
gp78 has opposite effects on lipid biosynthesis.
We here generated liver-specific gp78 knockout
(L-gp78/) mice and showed that although the
degradation of HMGCR was blunted, SREBP was
suppressed due to the elevation of Insig-1/-2, and
therefore the lipid biosynthesis was decreased. The
L-gp78/ mice were protected from diet-/age-
induced obesity and glucose intolerance. The livers
of L-gp78/ mice produced more FGF21, which
activated thermogenesis in brown adipocytes and
enhanced energy expenditure. Together, the major
function of gp78 in liver is regulating lipid biosyn-
thesis through SREBP pathway. Ablation of gp78
decreases the lipid levels and increases FGF21,
and is beneficial to patients with metabolic diseases.
INTRODUCTION
Cholesterol is synthesized from acetyl-CoA through a cascade of
enzymatic reactions. The biosynthesis of cholesterol is tightly
regulated, mainly through two feedback regulatory mechanisms:
sterol-regulated degradation of HMG-CoA reductase (HMGCR)
and maturation of sterol-regulatory element-binding protein
(SREBP) (Goldstein et al., 2006).
HMGCR catalyzes the conversion of HMG-CoA tomevalonate
that is a rate-limiting step in cholesterol biosynthesis (Goldstein
and Brown, 1990). Sterol promotes the degradation of HMGCR
through the ubiquitin-proteasome pathway, and therefore slows
down cholesterol biosynthesis (DeBose-Boyd, 2008). gp78 (also
known as autocrine motility factor receptor [AMFR]), an ERCelmembrane-anchored ubiquitin ligase, has been identified as
the E3 that ubiquitinates HMGCR (Song et al., 2005a, 2005b).
Through its transmembrane domain, gp78 interacts with another
ER membrane protein, Insig-1 or Insig-2 (Song et al., 2005b).
When the cholesterol level is low, HMGCR is kept apart from
Insig-gp78 complex and stabilized. A high level of sterol
promotes the interaction between HMGCR and Insig-1/-2, which
causes the ubiquitination of HMGCR by gp78 and subsequent
degradation (Song et al., 2005b). So it has been hypothesized
that gp78 may suppress cholesterol biosynthesis by targeting
HMGCR to degradation.
Besides HMGCR, gp78 also mediates the degradation of
Insig-1 protein. Insig-1 and -2 are key negative regulators of
sterol-regulated proteolysis of SREBP (Yang et al., 2002; Gold-
stein et al., 2006). There are three forms of SREBPs identified
in mammals: SREBP-1a, SREBP-1c, and SREBP-2 (Horton
et al., 2002). The SREBP is first synthesized as membrane-
bound transcription precursor (pre-SREBP), which forms
a complex with SREBP cleavage-activating protein (SCAP).
When cellular cholesterol level is high, Insig-1/-2 binds SCAP
and retains the SCAP-SREBP complex in ER (Goldstein et al.,
2006). When the cholesterol level is low, SCAP dissociates
from Insig-1/-2 and escorts SREBP to Golgi to undergo protease
cleavages. The released N-terminal transcriptional domain of
SREBP (nSREBP) enters the nucleus to activate transcription
of genes encoding proteins in lipid biosynthesis and uptake.
Meanwhile, Insig-1 is ubiquitinated by gp78 and degraded,
therefore creating a rapid and convergent regulation on choles-
terol biosynthesis and uptake (Lee et al., 2006b; Gong et al.,
2006). From this angle, degradation of Insig-1 by gp78 should
release the inhibition on SREBP and increase the biosynthesis
of lipid.
Thus, knockout of gp78 in vivo will have two opposite effects
on lipid metabolism: (1) increasing cholesterol biosynthesis by
stabilizing HMGCR, and (2) suppressing lipid synthesis by
elevating Insig levels to inhibit SREBP pathway. Here, we gener-
atedmicewith liver-specific deletion of gp78 (L-gp78/), as liver
is a major organ for lipid metabolism. Our study showed that the
degradation of HMGCR and Insig-1 was blunted in liver and
primary hepatocytes from L-gp78/ mice. Insig-2 protein level
was dramatically increased, as it is also a substrate of gp78.
Although HMGCR protein was increased, the SREBP pathwayl Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inc. 213
Figure 1. Metabolic Characteristics and
Gene Expression of L-gp78–/– Mice
Eight-week old male L-gp78/ mice and their
littermates were allowed ad libitum access to water
and chow diet prior to study. Error bars represent
standard deviations (SD). Statistical analysis was
done with the Student’s t test. *p < 0.05, **p < 0.01.
(A) Western blot analysis. Three major lobes and
total livers from each group (five mice per group)
were pooled, and the membrane and nuclear
extract fractions were subjected to immunoblot.
N, nuclear form; P, precursor.
(B) Activity of HMG-CoA reductase.
(C) Gene expression measured by qPCR.
(D) In vivo synthesis rates of sterols and FA in
different tissues of WT and L-gp78/ mice. Mice
(8-week-old male, three per group) were fasted for
12 hr and then refed a high-carbohydrate/low-fat
diet for another 12 hr prior to study. Each mouse
was then injected intraperitoneally with 3H-labeled
water (15 mCi in 150 ml of isotonic saline). One hour
later, the tissues were removed for measurement
of 3H-labeled sterols and FA.
(E) Metabolic parameters of these mice.
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thesis of cholesterol and fatty acid (FA). The L-gp78/ mice
were lean, with lower lipid levels in blood and tissues, and they
also displayed elevated energy expenditure (EE). These mice
were protected from diet- and age- induced obesity and glucose
intolerance.
RESULTS
Characterization of Liver-Specific gp78-Deficient Mice
To investigate the physiological function of gp78 in lipid metab-
olism, we used the Cre/loxP system to generate mice in which
gp78 is deleted exclusively in the liver. The gene targeting
strategy and validation were shown in Figure S1 (see online).
The liver-specific gp78-deficient mice are hereafter referred to
as L-gp78/. As controls, gp78f/f mice that do not express214 Cell Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inc.Cre recombinase (gp78f/f; Albumin-
Cre/) were used and referred to as
wild-type (WT). L-gp78/ mice were
born at the expected Mendelian ratios
and showed normal fertility. The gp78
protein was highly expressed in the livers
of WT mice but was lost specifically in the
livers of L-gp78/ mice (Figure S1D).
To evaluate the gp78 activity, we inves-
tigated the protein level of HMGCR.
In L-gp78/ mice, gp78 protein was
undetectable, and the HMGCR protein
was dramatically increased (Figure 1A),
consistent with the previous finding that
gp78 mediates the ubiquitination and
degradation of HMGCR (Cao et al.,
2007; Song et al., 2005b).
Furthermore, we analyzed the HMGCR
enzyme activity in liver homogenates. Asmost HMGCR molecules are inactivated by phosphorylation
(Brown et al., 1979; Kita et al., 1980), we homogenized the livers
in two different buffers. One of them contained sodium fluoride
(NaF), which inhibits the dephosphorylation during homogeniza-
tion and is believed to reflect the endogenous activity. The other
contained sodium chloride (NaCl), which permits dephosphory-
lation. To ensure complete dephosphorylation, we further
treated the microsomes with alkaline phosphatase to reveal
the maximal activity from HMGCR. In the NaF-contained buffer
without phosphatase treatment, the activity of HMGCR in
L-gp78/ mouse liver was 26% higher than in WT, although
both activities were very low (Figure 1B). After dephosphoryla-
tion, the HMGCR activity was greatly increased. The enzymatic
activity in L-gp78/ mouse liver was 1.5-fold higher than that
in WT (Figure 1B), which is consistent with the increase of
HMGCR protein.
Figure 2. Deficiency of gp78 Increases the
Stability of HMGCR, Insig-1, and Insig-2,
and Suppresses SREBP Pathway and De
Novo Lipid Biosynthesis in Primary Hepato-
cytes
Primary hepatocytes were isolated from WT and
L-gp78/ mice as described in the Experimental
Procedures. Error bars represent SD. Statistical
analysis was done with the Student’s t test. *p <
0.05, **p < 0.01.
(A) Western blot analysis.
(B) qPCR analysis.
(C) De novo biosynthesis of cholesterol and FA in
primary hepatocytes.
(D) Western blot analysis showing the sterol-regu-
lated degradation of endogenous HMGCR. On day
1, the cells were switched tomediumC. After 16 hr,
the cells were replaced with fresh medium C
containing the indicated concentration of 25-HC
and incubated for another 5 hr. Then the cells were
harvested, and the aliquots of whole-cell lysates
were subjected to immunoblot.
(E) Western blot analysis showing the sterol-regu-
lated ubiquitination of endogenous HMGCR. On
day 1, the cells were switched to medium C. After
16 hr, the cells were replaced with fresh medium C
containing the indicated concentration of 25-HC
plus 10 mMMG-132. After 1 hr, the cells were lysed
in HMGCR IP buffer and subjected to immuno-
precipitation with anti-HMGCR serum. Aliquots of
the immunoprecipitate and input were subjected to
immunoblot.
(F) Western blot analysis showing the degradation
of endogenous Insig-1 and Insig-2. On day 1, the
cells were switched to medium C. After 16 hr, the
cells were changed to the same fresh medium
containing 100 mM cycloheximide (CHX). At the
indicated time after CHX treatment, the cells were
harvested and subjected to immunoblot.
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in WT (Figure 1A), since gp78 promotes the degradation of Insig-
1(Lee et al., 2006b). Surprisingly, the Insig-2 protein level was
dramatically elevated (Figure 1A), suggesting that gp78 also
mediates the degradation of Insig-2. It has been reported that
Insig-2 is not degraded by gp78 in CHO cells and human fibro-
blasts (Lee et al., 2006b; Lee et al., 2006a), but no study has
been done using liver or hepatocytes. We will discuss this
phenomenon in more detail later (Figure 2 and Figure S2).
As Insig-1 and Insig-2 are negative regulators for SREBP pro-
cessing, the elevation of Insig-1/-2 decreased the levels of
nSREBP-1 (Figure 1A) and nSREBP-2 (Figure S1F). We exam-
ined the expression of multiple genes in liver by quantitative
PCR (qPCR). As shown in Figure 1C, the expression ofCell Metabolism 16, 213–2SREBP-1a, SREBP-1c, and SREBP-2
was decreased. Consistently, SREBP
target genes, including Insig-1, LDL
receptor (LDLR), the genes involved in
cholesterol synthesis (HMGCR, HMG-
CoA synthase [HMGCS], squalene syn-
thase [SS], and farnesyl diphosphate syn-
thase [FDS]), and the genes in FA andtriglyceride (TG) synthesis (fatty acid synthase [FAS], glycerol-
3-phosphate acyltransferase [GPAT], stearoyl CoA desaturase-
1 [SCD-1], and acetyl CoA carboxylase [ACC]) were all signifi-
cantly downregulated, while the non-SREBP target genes
including SCAP, Insig-2a, and Insig-2b were unchanged in
gp78-deficient livers compared with those in WT livers.
Interestingly, the LDLR mRNA level was reduced, but its
protein level remained unchanged in gp78-deficient livers
(Figures 1A and 1C). This can be explained by the dramatic
decline of the mRNA of proprotein convertase subtilisin/kexin
type 9 (PCSK9) and inducible degrader of the LDLR (IDOL),
which are SREBP target genes promoting the degradation of
LDLR (Zelcer et al., 2009; Lopez, 2008). Moreover, the LXR target
genes, including ABCG5 and ABCG8, were downregulated in25, August 8, 2012 ª2012 Elsevier Inc. 215
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biosynthesis that produces LXR agonists (Figure 1C) (Janowski
et al., 1996).
Since there is a dramatic increase of HMGCR protein and
a significant decrease of the mRNAs of many lipogenic genes
when gp78 is disrupted, would the lipid synthesis be affected?
To answer this question, the syntheses of sterol and FA in vivo
were determined by measuring the incorporation of intraperito-
neally injected 3H-labeledwater (Figure 1D). In liver, the synthesis
of sterol and FA was reduced by nearly 70% and 50% in
L-gp78/ mice, respectively (Figure 1D). The lipid synthesis in
kidney was unchanged (Figure 1D). In epididymal fat pads, the
sterol synthesis was unchanged, whereas the FA synthesis
was increased by 3-fold in L-gp78/ mice (Figure 1D). This
compensatory increase of FA synthesis in adipose tissue has
been similarly described in the study on liver-specific SCAP
knockout mice, which shows that the decreased FA synthesis
in liver is balanced by an increase in adipose tissue (Kuriyama
et al., 2005). However, the increase of FA synthesis in adipose
tissue can’t completely compensate for the decrease in liver
(Kuriyama et al., 2005). This is consistent with our observation
that the plasma FA was lower in L-gp78/ mice (Figure 1E).
The metabolic parameters of WT and L-gp78/ mice at the
age of 8 weeks old were measured (Figure 1E). The L-gp78/
mice showed the trend of less body weight, although the differ-
ence is not statistically significant. The liver weight was reduced
by 20%. The liver cholesterol concentration and total liver
cholesterol were decreased by 50% and 56% in L-gp78/
mice, respectively. Plasma total cholesterol (TC) in L-gp78/
mice was 26.2% lower than WT mice. The plasma TG, plasma
free FA, and liver TG were all declined in value, although there
were no statistical differences. Plasma insulin was unchanged,
but glucose level was decreased by 32% in L-gp78/ mice.
Overall, the L-gp78/ mice showed a favorable metabolic
profile comparing with the WT mice.
Together, the deficiency of gp78 in mouse liver increases the
protein level and enzymatic activity of HMGCR. Meanwhile,
both Insig-1 and Insig-2 protein levels are elevated, which
causes the suppression of SREBP processing and decreases
the expression of lipogenic genes. The net effect of gp78 defi-
ciency is decreasing lipid biosynthesis in liver.
Characterization of gp78-Deficient Primary
Hepatocytes
Primary hepatocytes of WT and L-gp78/mice were isolated to
further investigate the mechanism underlying the differences in
lipid metabolism. The patterns of protein and mRNA levels in
hepatocytes are similar to those of livers (Figures 2A and 2B).
The syntheses of cholesterol and FA were decreased by 66%
and 54%, respectively, in the gp78-deficient hepatocytes (Fig-
ure 2C), which is consistent with the decreased lipid synthesis
in gp78-deficient liver (Figure 1D) and the lower lipid levels in
L-gp78/ mice (Figure 1E).
We next measured the sterol-regulated degradation of
HMGCR. In WT primary hepatocytes, 25-hydroxycholesterol
(25-HC) promoted the ubiquitination and degradation of HMGCR
in a concentration-dependent manner, while these processes
were completely blunted in gp78-deficient cells (Figures 2D
and 2E). To eliminate the possible regulation at the transcrip-216 Cell Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inctional level, we measured the degradation of the transfected
HMGCR driven by a CMV promoter and got the consistent result
(Figure S2A). Taken together, these data demonstrate that
the stability of HMGCR protein is dramatically increased in
gp78/ cells.
Previous studies reported that gp78mediates the degradation
of Insig-1 but not Insig-2. Those experiments were performed in
SV589 (a fibroblast cell line) or CHO cells (Lee et al., 2006a,
2006b). However, we here found that both endogenous Insig-1
and Insig-2 were rapidly degraded in WT primary hepatocytes
with a half-life of 3 hr (Figure 2F), and their stabilities were
significantly increased in gp78-deficient cells (Figure 2F). Addi-
tionally, transfected Insig-1 and Insig-2 driven by a TK promoter
showed similar degradation pattern as endogenous proteins in
primary hepatocytes (Figures S2B and S2C). We further
compared the degradation pattern of Insig-1/-2 in CHO-7 and
hepatocyte CRL-1601 cells. The results showed that Insig-1
was a short-lived protein in both cell lines. In contrast, Insig-2
was a stable protein in CHO-7 but not in CRL-1601 (Figure S2D),
suggesting that Insig-2 may be specifically degraded by gp78 in
liver cells.
Knockdown of Insig-2 Reverses Most of the Phenotypes
in L-gp78–/– Mice
The above data show that the suppressive effect on SREBP
pathway is dominant in mouse liver when gp78 is deficient.
Although both HMGCR and Insigs are substrates of gp78 in lipid
metabolism, it is still possible that other unidentified substrates
of gp78 contribute to these phenomena. To exclude this possi-
bility and further confirm that the phenotypes we observed on
L-gp78/ mice are due to the stabilization of Insigs, we per-
formed RNAi experiments in vivo.
Since Insig-2 was dramatically increased and Insig-1 was only
moderately increased in gp78-deficient liver (Figures 1A), we
utilized adenovirus-mediated RNAi to reduce the expression
of Insig-2 in mice livers. The short hairpin (shRNA) targeting
Insig-2 massively reduced the expression of Insig-2 (Figure 3A,
sixth panel) but had no obvious effect on HMGCR level (Fig-
ure 3A, third panel). Furthermore, knockdown of Insig-2 caused
an increase of nSREBP-1 (Figure 3A, second panel). The
nSREBP-1 level in L-gp78/ mice receiving Insig-2 shRNA
was almost the same as that inWTmice receiving control shRNA
(Figure 3A, second panel, compare lanes 4 and 1). Importantly,
the plasma concentrations of TC and TG in L-gp78/ mice
receiving Insig-2 shRNA were increased to the levels similar to
those in WT mice receiving control shRNA (Figures 3B and 3C).
The TC and TG levels in the livers of L-gp78/ mice were also
restored by Insig-2 RNAi (Figures 3E and 3F). Consistent with
the changes of nSREBP-1 (Figure 3A), the expression of all
the measured lipogenic genes including HMGCR, HMGCS,
squalene epoxidase (SE), farnesyl diphosphate farnesyl trans-
ferase-1 (FDFT-1), FAS, GPAT, and SCD-1 were increased in
Insig-2 shRNA-treated mice, and their expression levels in
L-gp78/ mice were almost completely restored by Insig-2
RNAi (Figure 3G, compare fourth and first columns for every
gene). The activities of alanine transaminase (ALT) and glutamic
oxaloacetic transaminase (GOT) in blood were unchanged, sug-
gesting that administration of adenovirus had no measurable
damage to mice livers (Figures 3H and 3I)..
Figure 3. Knockdown of Hepatic Insig-2
Reverses the Phenotypes of L-gp78–/– Mice
Twenty-week-old male L-gp78/ mice and their
littermates (four per group) were allowed ad libitum
access to water and chow diet. The mice were
subjected to caudal vein injection with titer of 8 3
108 adenoviral virus expressing a shRNA against
Insig-2 or a control shRNA. After an additional
5 days, the mice were sacrificed and analyzed.
Error bars represent SD. Statistical analyses were
done using two-way ANOVA (Tukey HSD post
test). ns, no statistically significant differences. +p <
0.05, ++p < 0.01 Ad-shInsig-2 versus Ad-shControl;
*p < 0.05, **p < 0.01 L-gp78/ mice versus WT.
(A) Western blot analysis of livers.
(B–F) Measurement of blood total cholesterol (TC),
blood TG, liver weight, liver TC, and liver TG.
(G) Gene expression in liver measured by qPCR.
WT mice injected with adenovirus-expressing
control shRNA were arbitrarily defined as 1.
(H and I) The activities of alanine transaminase
(ALT) and glutamic oxaloacetic transaminase
(GOT) of every group of mice in blood.
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phenotypes of L-gp78/ mice are due to the increase of Insigs
that in turn suppresses SREBP pathway.
Effect of Fasting and Refeeding on Metabolic Process
in WT and L-gp78–/– Mice
Previous studies showed that the processing of SREBP was
regulated by fasting and refeeding (Engelking et al., 2004). To
examine this physiological regulation, L-gp78/ mice and its
WT littermates were subjected to fasting and refeeding proce-
dure. Consistent with previous report, the precursor and nuclear
forms of SREBP-1c in WT mice were reduced by fasting (Fig-
ure 4A, first and second panels, lane 2), and a major ‘‘over-
shoot’’ in nSREBP-1c was induced by refeeding (Figure 4A,
second panel, lane 3). In contrast, the L-gp78/ mice exhibited
a slight reduction in nSREBP-1c in the nonfasted group (Fig-
ure 4A, second panel, compare lanes 4 and 1), and there was
further decline of pre-SREBP1 and n-SREBP1 with fasting (Fig-
ure 4A, first and second panels, lane 5). At refeeding, the
L-gp78/ mice showed a much smaller overshoot than did
the WT littermates (Figure 4A, second panel, compare lanes 6Cell Metabolism 16, 213–2and 3). Similar to the previous reports
(Engelking et al., 2004; Yabe et al.,
2003), in the WT mice, fasting resulted
in the disappearance of HMGCR and
Insig-1 (due to the decrease in nSREBPs)
and the increase of Insig-2 (due to the
decrease in insulin) (Figure 4A, third to
fifth panels, lanes 1–3). However, Insig-2
in L-gp78/ mice was dramatically
increased and kept consistent in different
treatments (Figure 4A, fifth panel, lanes
4–6). There was a slight increase of
HMGCR and Insig-1 in gp78-deficient
mice, and they were similarly regulatedby fasting and refeeding as in WT mice (Figure 4A, third and
fourth panels, lanes 4–6).
The mRNA levels of relevant genes were analyzed. At non-
fasted condition, the SREBP target genes including SREBP-1c,
SREBP-2, Insig-1, HMGCR, HMGCS, FDS, SS, LDLR, ACC,
FAS, SCD-1, and GPAT were all lower in L-gp78/ than in
WT mice. Fasting caused the repression of these genes in
both WT and L-gp78/ groups. Since there was an overshot
of nSREBP-1 in refed WT mice, refeeding caused marked
increases in all of the measured mRNAs encoding enzymes of
FA and TG synthesis. However, this regulation was severely
blunted in L-gp78/ mice. In both groups, refeeding sup-
pressed the expression of Insig-2a and phosphoenolpyruvate
carboxykinase (PEPCK), two genes known to be repressed
by insulin (Yabe et al., 2003). As a control, the mRNA of apolipo-
protein E (apoE) was not affected by fasting and refeeding in WT
or L-gp78/mice. The levels of lipids, glucose and insulin were
also measured and are shown in Table S1.
These results indicate that the gp78 deficiency in mouse
liver elevates Insig-2 level and suppresses the overshoot of
nSREBP-1 in refeeding condition, which is consistent to the25, August 8, 2012 ª2012 Elsevier Inc. 217
Figure 4. Effects of Fasting and Refeeding on the Livers of WT and L-gp78–/– Mice
Twelve-week-oldmale L-gp78/mice and their littermates (six per group) were subjected to fasting and refeeding. The nonfasted group (NF) was fed a chowdiet
ad libitum, the fasted group (F) was fasted for 12 hr, and the refed group (R) was fasted for 12 hr and then refed a high-carbohydrate/low-fat diet for 12 hr. Detailed
metabolic parameters of these mice are provided in Table S1.
(A) Western blot analysis of livers. P, precursor; N, nuclear.
(B) Gene expression in liver measured by qPCR.
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Knockout of gp78 Inhibits SREBP Pathwayobservation in Insig-1 liver-specific transgenic mice (Engelking
et al., 2004). The suppression of SREBP results in the downregu-
lation of genes in lipid biosynthesis (Figure 4B) and the lower lipid
levels in plasma and liver in L-gp78/ mice (Table S1).
L-gp78–/– Mice Exhibit Elevated Energy Expenditure
and Are Resistant to Diet-Induced Obesity
To assess the role of gp78 in metabolic diseases, we examined
the physical andmetabolic features of L-gp78/mice after diet-
induced obesity (DIO). The 8-week-old male mice were fed on218 Cell Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inca western-type diet (WD) for 15 weeks. During this process,
the WT mice gained weight more rapidly than the L-gp78/
mice (Figure 5A), although they had similar starting weights. After
15 weeks on WD, the WT mice had gained 59% of their starting
weight, whereas the L-gp78/ mice only gained 29% (Fig-
ure 5A), suggesting that the L-gp78/ mice are resistant to
DIO. The body composition study revealed that the fat/body
weight of L-gp78/ mice was 36% lower than that of control
mice, while the lean/body weight was similar between the two
groups (Figure 5C). Interestingly, although the L-gp78/ mice.
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mice. The fecal cholesterol and TG levels were similar between
two groups (Figure S3C), indicating that the dietary absorption
of lipids was unaltered in the L-gp78/ mice. Therefore, the
L-gp78/ mice acquired more energy with lower body weight
gain.
To determine the underlying mechanism, we analyzed the
whole animal metabolism using metabolic cages. No significant
differences were detected in the physical activity and respiratory
quotient (RQ) between the WT and L-gp78/ mice (Figures 5D
and 5E). Importantly, ANCOVA analysis uncovered that the EE
of L-gp78/ mice was 16.1% higher than that of WT mice
(Tschop et al., 2012) (Figure 5F). This result suggested that the
elevated EE may be a mechanism of the DIO-resistance pheno-
type of L-gp78/ mice.
When exposed to a cold environment, the ability of L-gp78/
mice to maintain body temperature was higher compared
with WT mice (Figure 5G), suggesting that the thermogenesis
of L-gp78/ mice was higher. Since brown adipocyte tissue
(BAT) is a major tissue for thermogenesis, we analyzed the
expression of multiple genes in BAT. The expression of genes
encoding proteins involved in mitochondrial oxidation and
BAT thermogenic activation (e.g., uncoupling protein1 [UCP-1],
carnitine palmitoyltransferase 2 [Cpt2], cytochrome c [Cyt c],
and peroxisome proliferative activated receptor, gamma, coacti-
vator 1 alpha [PGC-1a]) was higher in L-gp78/mice than inWT
mice. The mRNA of glucose transporter 4 (GLUT4) was also
significantly higher in L-gp78/ mice, suggesting an increased
utilization of glucose (Figure 5H).
Collectively, loss of hepatic gp78 results in BAT activation and
an increase in EE. Hence, the L-gp78/ mice are protected
against DIO.
Loss of Hepatic gp78 Decreases Lipid Levels
and Increases Insulin Sensitivity
At the end of DIO, the WT mice were obviously fatter than the
L-gp78/ mice (Figure S3A). Gross appearance at sacrifice
revealed that the fat mass in L-gp78/ was lower than that in
WT mice (Figure S3B). The weight of epididymal WAT from
L-gp78/ mice was 56% less than that from WT (Figure 5M).
Histological analysis of liver showed that there were remarkably
fewer lipid droplets in L-gp78/ mice (Figure S3D, top panel).
Moreover, the size of white and brown adipocytes of L-gp78/
mice was substantially smaller than that of WT (Figure S3D,
middle and bottom panels). The protein and mRNA levels in
the livers were measured and showed a similar trend of differ-
ence (Figures S3E and S3F) as that observed in chow diet-fed
mice (Figure 1).
Next, the lipid levels in blood and other tissues were deter-
mined. As described in Figure 5M, plasma cholesterol (24%),
TG (38%), and free FA (14%) levels in the L-gp78/ mice were
dramatically lower than those inWT. Consistently, FPLC analysis
showed that the cholesterol and TG in VLDL, LDL, and HDLwere
all lower in L-gp78/mice (Figure 5N). The liver cholesterol and
TG concentrations were 32% and 22% lower in L-gp78/ mice
than those in WT mice, respectively. The total liver cholesterol
and TG levels were also lower in L-gp78/ mice, and the differ-
ence was as high as 50%. The plasma insulin and glucose
levels were 40% lower (Figure 5M). Moreover, as shown inCelFigures 5I–5L, the glucose tolerance and insulin resistance in
L-gp78/ mice were significantly improved as measured by
glucose tolerance test (GTT) and insulin tolerance test (ITT).
Thus, liver-specific knockout of gp78 leads to beneficial
effects in both lipid and glucose metabolism in DIO mice.
L-gp78–/– Mice Display Lower Lipid Levels and Are
Protected from Age-Induced Obesity and Glucose
Intolerance
As obesity is often correlated with aging, we next measured
whether L-gp78/ mice were protected against age-induced
obesity. The mice were fed on chow diet for 40 weeks and
then subjected to analysis. The L-gp78/ mice were lean, with
less fat compared to the WT mice (Figures 6A–6C). Metabolic
cage experiments revealed that the physical activity and RQ of
the two groups were similar (Figures 6D and 6E). But the EE,
statistically analyzed using ANCOVA, was dramatically (79.3%)
higher in L-gp78/ mice than that in WT mice (Figure 6F).
In a cold environment, the ability of L-gp78/ mice to maintain
body temperature was stronger (Figure 6G). Furthermore,
the expression of genes involved in mitochondrial function,
FA oxidation, and thermogenesis (e.g., UCP-1, Cpt2, Cyt c,
medium-chain acyl-CoA dehydrogenase [MCAD], hormone-
sensitive lipase [HSL], and PGC-1a) was higher in the BAT of
L-gp78/ mice than in the BAT of WT mice. The GLUT4
mRNA was also markedly higher (Figure 6H).
The body weight, liver weight, and epididymal fat weight were
36%, 40%, and 80% lower in L-gp78/mice, respectively. The
liver cholesterol and TG concentrations were 36% and 22%
lower, respectively. Strikingly, the total liver cholesterol and TG
of L-gp78/ mice were 63% and 45% lower than those of WT
mice. Compared with those in WT mice, the plasma cholesterol
(34%), TG (34%), free FA (20%), insulin (49%), and glucose
(42%) levels were all significantly lower in L-gp78/ mice (Fig-
ure 6M). In addition, glucose tolerance and insulin resistance
were significantly improved in the L-gp78/ mice compared
with the WT mice as determined by GTT and ITT (Figures
6I–6L). As shown in Figures S4A and S4B, the gene expression
difference between L-gp78/ and WT mice under chow diet
was similar to that under Western-style diet (Figure S3).
One concern on the leanness of mice is that it can be caused
by sickness. To rule out this possibility, the inflammatory factors
including IL-1b and IL-6 weremeasured, andwe found theywere
unchanged in L-gp78/ mice (Figures S1E, S3I, S3J, and S4E),
suggesting the leanness is not due to illness. Furthermore, the
heterozygous (L-gp78+/) mice were also analyzed on multiple
metabolic features. Their gross appearances, gene expression,
and metabolic parameters showed the intermediate phenotypes
(Figure S5), indicating a gene dosage effect of gp78 on these
aspects. Together, these data demonstrate that L-gp78/
mice display lower lipid levels and are protected from age-
induced obesity and glucose intolerance.
Elevated Expression of FGF21 in the Liver of L-gp78–/–
Mouse May Contribute to the Thermogenic Activation
of BAT
In the aforementioned measurements of EE, relatively old mice
were used, and the two groups of mice had dramatic differences
in body weight and body composition (Figure 5 and Figure 6). Tol Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inc. 219
Figure 5. L-gp78–/–Mice Display Resistance to Diet-Induced Obesity, Increased Energy Expenditure, Decreased Lipid Levels, and Improved
Insulin Sensitivity
Male L-gp78/mice and their WT littermates at 8 weeks of age were grouped (five per group). Mice were allowed ad libitum access to water and western-type
diet (WD) (normal chow supplemented with 1.25% cholesterol, 20% fat, and 0.5% cholic acid, w/w). After 15 weeks of treatment, the mice were placed into
metabolic chambers to measure oxygen consumption, CO2 production, physical activity, etc., at ambient temperature (23
C). In all panels, error bars represent
SD. Statistical analyses were done with the Student’s t test. *p < 0.05, **p < 0.01.
(A) Body weight (BW) per mouse during the 15 week experiments.
(B) ANCOVA-estimated food intake for each genotype at a common BW of 25.7 g.
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Figure 6. L-gp78–/–Mice Display Resistance
to Age-Induced Obesity, Increased Energy
Expenditure, Decreased Lipid Levels, and
Improved Insulin Sensitivity
Male L-gp78/ mice and their WT littermates
were grouped (five per group) and fed a chow diet
ad libitum for 40 weeks. After 40 weeks of treat-
ment, the mice were placed into metabolic cham-
bers to measure oxygen consumption, CO2
production, physical activity, etc., at ambient
temperature (23C). In all panels, error bars
represent SD. Statistical analyses were done with
the Student’s t test. *p < 0.05, **p < 0.01.
(A) Body weight per mouse at the ages of 10 weeks
and 40 weeks.
(B) A representative photograph of the 40-week-
old mice.
(C) Whole-body composition of the 40-week-old
mice determined by NMR.
(D) Physical activity per mouse was recorded.
(E) RQ was recorded.
(F) ANCOVA-estimated EE for each genotype at
a common lean body mass of 22.3 g.
(G) Body temperature of the mice at different times
after cold exposure (4C).
(H) Gene expression in BAT determined by qPCR.
(I) GTT was performed with the 40 week chow diet-
fed mice.
(J) The AUC of the GTT in (I) was quantified.
(K) ITT was performed with the 40 week chow diet-
fed mice.
(L) The AUC of the ITT in (K) was quantified.
(M) Metabolic parameters of WT and L-gp78/.
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phenotype of L-gp78/ mice and to eliminate the effects of
body weight and body composition, we applied 16-week-old
mice to the whole-animal metabolic studies, since the WT and
L-gp78/mice showed similar body weight and body composi-
tion at this age (Figures 7A and 7B). Their RQ and physical
activity were identical (Figures 7C and 7D). However, the EE of
L-gp78/ mice was already 18.8% higher than that of WT(C) Whole-body composition of the mice after 15 week WD treatment determined by NMR.
(D) Physical activity per mouse was recorded.
(E) Respiratory quotient (RQ) was recorded.
(F) Energy expenditure (EE) was calculated using the equation ofWeir, EE (Kcal/hr) = (3.8183 VO2) + (1.2323V
a common lean body mass of 19.7 g.
(G) Body temperature of the mice at different times after cold exposure (4C).
(H) Gene expression in brown adipose tissue (BAT) determined by qPCR.
(I) Glucose tolerance test (GTT) was performed with the 15 week Western diet-fed mice.
(J) Quantification of the area under the curve (AUC) of the GTT in (I).
(K) Insulin tolerance test (ITT) was performed with the 15-week Western diet-fed mice.
(L) Quantification of the AUC of the ITT in (K).
(M) Comparison of metabolic parameters of WT and L-gp78/.
(N) The graph represents TC and TG concentrations in fast performance liquid chromatography (FPLC) frac
Cell Metabolism 16, 213–2mice (Figure 7E), indicating that the differ-
ence of EE appears before the difference
of the body weight.
It has been shown that cold can
significantly increase energy metabolism
(Tschop et al., 2012; Cannon and Neder-gaard, 2011). The aforementioned experiments were conducted
at a room temperature (23C) that is a chronic cold stress to
mice. Therefore, we further performed a metabolic cage study
at thermoneutrality (30C) to rule out the interference of the
cold-induced thermogenesis. At thermoneutrality, no significant
differences were detected in the physical activity and RQ
between the WT and L-gp78/ mice (Figures 7F and 7G). Inter-
estingly, although the EE of both WT and L-gp78/ mice wasCO2). ANCOVA-estimated EE for each genotype at
tions from the serum of WT and L-gp78/.
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Figure 7. Elevated Expression of FGF21 in the Liver of L-gp78–/– Mouse May Contribute to the Thermogenic Activation of BAT
Male L-gp78/mice and theirWT littermates were grouped (six per group) and fed a chow diet ad libitum for 16weeks. Themice were then placed intometabolic
chambers to measure oxygen consumption, CO2 production, physical activity, etc. From I-P, the mice were fasted for 12 hr before subjected to analysis. In all
panels, error bars represent SD. Statistical analyses were done with the Student’s t test. *p < 0.05, **p < 0.01.
(A) Body weight per mouse at the age of 16 weeks.
(B) Whole-body composition of the 16-week-old mice determined by NMR.
(C and D) RQ and physical activity per mouse was recorded at 23C.
(E) ANCOVA-estimated EE for each genotype at 23C. Covariates are evaluated at the following values: lean body mass, 17.2 g.
(F and G) RQ and Physical activity per mouse was recorded at 30C.
(H) ANCOVA-estimated EE for each genotype at 30C. Covariates are evaluated at the following values: lean body mass, 17.2 g.
(I) Gene expression in BAT was determined by qPCR. Dio2, 50-deiodinase-2.
(J–N) Serum levels of T3, epinephrine, norepinephrine, FGF21, and ketone body.
(O) Gene expression in liver determined by qPCR.
(P) The FGF21 level in liver determined by western blot.
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24.7% higher EE than WT mice at 30C (Figure 7H). One step
further, we performed a 6 week DIO experiment under 23C
and 30C. Both WT and L-gp78/ mice gained more weight
and ate less at 30C (Figures S6A and S6B). The L-gp78/222 Cell Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Incmice were lighter than WTmice at both 23C and 30C, although
the difference is smaller at 30C (Figure S6A). Consistent with the
data in Figure 5, the food intake of L-gp78/ mice was still
higher than that of WT at both 23C and 30C (Figure S6B), sug-
gesting there was a compensatory increase of food intake for.
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the increased EE in L-gp78/ mice is not dependent on body
weight, body composition, environmental temperature, or diet
type. Hepatic loss of gp78 per se is a driver for the increased EE.
Since the L-gp78/mice showed a higher EE with similar
physical activity compared with the WT mice, we next examined
the molecular differences of BAT between the two groups of
16-week-old mice. The expression of genes involved in mito-
chondrial function, FA oxidation, and thermogenenic activation
were all higher in the BAT from L-gp78/ mice (Figure 7I).
It is interesting that the deletion of gp78 in liver increases BAT
thermogenesis. We next sought to identify the potential mecha-
nism. Previous studies have reported that BAT can be activated
by a variety of factors, including 3, 5, 30-triiodothyronine (T3)
(Obregon, 2008); epinephrine, norepinephrine (Robidoux et al.,
2004); fibroblast growth factor 21 (FGF21) (Kharitonenkov and
Larsen, 2011); Irisin (Bostrom et al., 2012); Orexin (Sellayah
et al., 2011); and bone morphogenetic protein 7 (BMP7) (Tseng
et al., 2008). To identify which mediates the activation of BAT
in L-gp78/ mice, we measured their serum levels and/or
hepatic expression. The serum concentrations of T3, epineph-
rine, and norepinephrine were similar in WT and L-gp78/
mice (Figures 7J–7L); so was the hepatic expression of Irisin,
Orexin, and Bmp7 (Figure 7O). On the contrary, the serum
FGF21 level was 62.2% higher in L-gp78/ mice (Figure 7M).
FGF21 is mainly produced by the liver and can activate the
thermogenesis of BAT (Fisher et al., 2012; Hondares et al.,
2010; Nishimura et al., 2000). Consistently, FGF21 mRNA in
L-gp78/ liver was 3-fold higher than that inWT liver (Figure 7O).
The hepatic mRNA and serum levels of FGF21 were also signif-
icantly higher in L-gp78/ mice compared with those in WT
mice after 6 weeks of DIO at both 23C and 30C (Figures S6D
and S6E).
In summary, the increased EE is an intrinsic feature of
L-gp78/ mice, and the BAT activation is likely driven by the
increased FGF21 expression and secretion from gp78/
hepatocyte.
DISCUSSION
The current studies demonstrate that hepatic gp78 plays an
essential role in regulating lipid and energy metabolism in
animals. On one hand, deletion of gp78 in liver greatly increases
the amount and activity of HMGCR; on the other hand, Insig
protein levels (especially Insig-2) are significantly elevated,
which results in the suppression of SREBP pathway. The net
effect is the decrease of biosynthesis of cholesterol and FA in
liver. Meanwhile, deficiency of gp78 increases the expression
and secretion of hepatic FGF21 that activates the thermogenesis
of BAT. Together, the mice with liver-specific deletion of gp78
displayed lower lipid levels, higher EE, improved insulin sensi-
tivity, and resistance to diet-/age-induced obesity.
gp78 has been recognized as a key E3 in ER-associated
degradation (ERAD) that is part of the ER quality control system
(St. Pierre and Nabi, 2011). Interestingly, in our study, the
unfolded protein response (UPR) was not elevated in gp78-defi-
cient liver, as the Bip protein was not elevated in chow diet-fed or
WD-fed mice (Figure 1A, Figure S3E). It is probably because
other E3s can compensate for the role of gp78 in ERAD. It isCelalso possible that the UPR would become dramatic upon certain
stresses. Nevertheless, under the conditions in our study, gp78
is mainly involved in lipid homeostasis.
Although both Insig-1 and Insig-2 are degraded by gp78 in
liver, the amount of Insig-2 protein is dramatically increased,
but Insig-1 is only moderately elevated in gp78-deficient cells
and liver. One reason may be that the Insig-1 gene, but not
the Insig-2 gene, is regulated by SREBP (Yabe et al., 2002,
2003). The stabilization of Insigs leads to the suppression of
SREBPs. In turn, as a SREBP target gene, Insig-1 is transcrip-
tionally downregulated (Figure 1C, Figure 2B, Figure S3G,
and Figure S4C), which blunts the effect of increased Insig-1
stability. On the contrary, the Insig-2 mRNA level is not affected
by this feedback, and therefore the Insig-2 protein is hugely
upregulated. The marked increase of Insig-2 protein is the
critical cause of inhibition of SREBP pathway, as Insig-2 shRNA
almost completely reversed the phenotypes of L-gp78/ mice
(Figure 3).
It is worth noting that we discovered that Insig-2 is a liver-
specific substrate of gp78 using the liver gp78 knockout mice.
We have further validated this phenomenon in rat hepatocyte
cell line CRL1601. Therefore, the gp78-deficient liver can be
a useful tool to identify novel gp78 substrates and study their
functions. In addition to HMGCR and Insigs, gp78 has also
been reported to mediate the degradation of other proteins,
including apoB, CYP3A, CYP2E1, KAI1, CFTRDF508, mutant
huntingtin, mutant neuroserpin, mutant SOD1, ataxin-3, ATZ,
and cholera toxin. Thus, gp78 may be involved in a variety of
physiological and pathological processes, such as lipoprotein
metabolism, pharmacokinetic profiles of anticancer agents,
tumor metastasis, Huntington’s disease, familial encephalop-
athy, and neurodegeneration diseases. The gp78-floxed mice
generated here will be a useful tool to explore those functions
after being crossed with related CRE mice lines.
The L-gp78/ mice are protected from diet-/age-induced
obesity (Figure 5 and Figure 6). These phenotypes are different
from the SREBP-1c/ mice that didn’t display resistance to
DIO (Yahagi et al., 2002; Shimano et al., 1997). Although both
lines of knockout mice showed decreased SREBP-1c in liver, it
is worth noticing that there was significant upregulation of
SREBP-2 in the SREBP-1c knockout mice. Hence, it is likely
that the effects of SREBP-1 deficiency can be partially compen-
sated by the increase of nSREBP-2. In contrast, our gp78
knockout mice showed the decrease of both SREBP-1 and
SREBP-2 (Figure 1A, Figure S1F).
Intriguingly, the L-gp78/ mouse exhibits increased EE with
activated thermogenesis of BAT. In this mouse, the hepatic
expression of FGF21 was dramatically increased. FGF21 can
stimulate thermogenesis in BAT through activating the expres-
sion of UCP1, PGC1a, Dio2, Cyt c, Glut4, and other genes.
How can the loss of gp78 increase the expression of FGF21 in
liver? It has been reported that peroxisome proliferator-activated
receptor alpha (PPARa) has a major role in the control of FGF21
expression (Badman et al., 2007; Inagaki et al., 2007). However,
the expression of three other PPARa target genes, including
acyl-CoA oxidase 1 (ACOX1), carnitine palmitoyltransferase 1a
(Cpt1a), and HMGCS2 was similar in the liver of WT and
L-gp78/ mice, suggesting that the elevated expression of
FGF21 is not mediated through PPARa. Interestingly, it hasl Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Inc. 223
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(Zhang et al., 2011). Given that the SREBP pathway is inhibited
in gp78-deficient cells, it is highly possible that the increased
FGF21 expression is due to the decrease of nSREBP. In support
of this notion, knockdown of Insig-2 increased nSREBP level and
decreased the expression of FGF21 in liver (Figure 3G). The
gp78-SREBP-FGF21 axis is of great significance, as it may
provide the mechanism of the systematic balance between lipid
biosynthesis and energy consumption.
Our previous study has demonstrated that inhibition of SREBP
pathway by a small compound, betulin, can prevent DIO and
increase energy metabolism (Tang et al., 2011). It is likely that
betulin also works through the increase of FGF21 in mice, and
this is under investigation. One potential caveat is that we cannot
exclude the possible involvement of other unknown factors.
Further experiments are needed to address whether there are
other proteins secreted by the liver to regulate metabolism of
BAT in L-gp78/ mouse.
Taken together, ablation of gp78 in liver leads to inhibition of
SREBP pathway, decrease of lipid biosynthesis, increase of
EE, and resistance to diet-/age-induced obesity. These results
are nicely aligned with the previous finding that inhibition of
SREBP pathway has beneficial effects on lipid and glucose
metabolism (Tang et al., 2011). Thus, inhibition of gp78 may
provide a therapeutic avenue to suppress SREBP pathway to
treat metabolic diseases including hyperlipidemia and type II
diabetes.
EXPERIMENTAL PROCEDURES
A complete description of materials and other methods is available in the
Supplemental Experimental Procedures.
Generation of Control and Liver-Specific gp78 Knockout Mice
A floxed gp78 allele was created in embryonic stem cells of the 129S1/SvlmJ
mouse strain by introducing loxP sites into the introns flanking exon 5 and 8 of
gp78, using a neo cassette (G418 resistance) surrounded by FRT sites as
a selectable marker (Figure S1A). Stem cells in which homologous recombina-
tion had taken place were selected by G418 resistance, and the recombination
was confirmed by Southern blot analysis (data not shown). The targeted stem
cells were injected into blastocysts of C57BL/6J mice to gain chimeric mice.
After germline transmission, the mice were crossed to C57BL/6J mice
expressing flp recombinase to remove the neo cassette. Filial generations
containing a floxed gp78 allele deleting the neo cassette were further back-
crossed to C57BL/6J mice for at least ten generations. Then homozygous
gp78f/f mice were crossed with transgenic C57BL/6J mice expressing cre
recombinase driven by albumin (alb) promoter, which is active exclusively in
liver. Next, resulting progeny (gp78f/+ alb-creTg/) were mated with gp78f/f
mice to generate liver specific gp78 knockout mice (L-gp78/). Littermates
who lacked the cre gene (gp78f/f; Albumin-Cre/) were used as WT.
Animals and Treatment
All animals were maintained and used in accordance with the guidelines of the
Institutional Animal Care andUseCommittee of the Shanghai Institutes for Bio-
logical Sciences. Mice were treated as described in the figure legends.
Metabolic Measurements
Measurements of oxygen consumption (VO2) and RQ with indirect calorimetry
were performed on mice. Animals were maintained on a standard chow diet or
WD under 12 hr light and dark cycles beginning at 6:00 a.m. and 6:00 p.m.,
respectively. Mice were acclimated in a comprehensive lab animal monitoring
system (Columbus Instruments, Columbus, OH) for 1 day before recording
according to the instructions of the manufacturer. Measurements of VO2224 Cell Metabolism 16, 213–225, August 8, 2012 ª2012 Elsevier Incwere recorded over 2 days. RQ equals [volumes of CO2 released] / [volumes
of O2 consumed]. The analyses were normally performed at ambient temper-
ature (23C) unless specifically mentioned.
Glucose Tolerance and Insulin Tolerance Tests
Prior to studies, mice were fasted overnight (GTT) or for 4 hr (ITT). In GTT
studies, mice were injected intraperitoneally with a D-glucose solution (2 g/kg
body weight). For ITT, mice received an intraperitoneal injection of insulin
(Sigma) (0.75 U/kg body weight). Tail blood glucose levels were measured at
0, 15, 30, 60, and 120 min after challenge using the Onetouch Ultra blood
glucose monitoring system (LifeScan).
Blood and Liver Chemistry
Serum glucose, TC, and total TG levels were determined according to the
manufacturer’s instructions (KINGHAWK, China). Free FA was enzymatically
measured with a kit (NEFA, Wako, Japan). Liver tissues were homogenized,
and centrifuged supernatants were harvested. The TC and TGs were deter-
mined. The serum levels of insulin, adiponectin, ALT, GOT, T3, epinephrine,
norepinephrine, ketone body, and FGF21 were measured by ELISA (Antibody
and Immunoassay Services, HKU; R&D Systems).
Histology
Livers of mice were embedded in Tissue-Tek OCT cryostat molds (Leica) and
frozen at 80C. These 10 mm thick sections of livers were generated in
a cryostat. Tissue sections were stained in 0.5% oil red O and counterstained
with Mayer’s hematoxylin. Adipose tissues were embedded in paraffin and
sectioned at 5 mm onto poly-L-lysine-coated slides. Then sections were
stained with hematoxylin and eosin.
Fast Performance Liquid Chromatography
For determination of the lipid distribution over plasma lipoproteins by fast
performance liquid chromatography (FPLC), 150 ml of pooled plasma from
four mice per group was diluted with 450 ml PBS. Then total diluted serum
was injected onto a Superose 6 10/300 GL column (GE Healthcare Bio-
Sciences AB) and eluted at a constant flow rate of 0.2 ml/min PBS. Fractions
of 200 ml were collected and assayed for TC and TGs.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at http://dx.doi.org/10.1016/j.cmet.2012.06.014.
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